These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36251231)

  • 1. Clinical characteristics of steroid-responsive but dependent chronic graft-versus-host disease: a multicenter retrospective analysis.
    Oyama T; Matsuda K; Honda A; Maki H; Masamoto Y; Murakami D; Toya T; Sakurai M; Kataoka K; Doki N; Kurokawa M
    Int J Hematol; 2023 Feb; 117(2):260-268. PubMed ID: 36251231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steroid-Refractory Chronic Graft-Versus-Host Disease: Treatment Options and Nursing Care.
    Cazeau N; Rodriguez S
    Clin J Oncol Nurs; 2023 May; 27(3):259-265. PubMed ID: 37267484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.
    Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease.
    Belina ME; Driscoll TA; Blanchard SK; Cardones AR
    Pediatr Dermatol; 2022 May; 39(3):432-433. PubMed ID: 35234308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeated Infusions of Bone-Marrow-Derived Mesenchymal Stem Cells over 8 Weeks for Steroid-Refractory Chronic Graft-versus-Host Disease: A Prospective, Phase I/II Clinical Study.
    Kim N; Min GJ; Im KI; Nam YS; Song Y; Lee JS; Oh EJ; Chung NG; Jeon YW; Lee JW; Cho SG
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Multicenter, Retrospective Study Evaluating Clinical Outcomes of Ruxolitinib Therapy In Heavily Pretreated Chronic GVHD Patients With Steroid Failure.
    White J; Elemary M; Linn SM; Novitzky-Basso I; Culos S; Tan SK; Kelly K; Deotare U; Xenocostas A; Hamad N; Law A; Kumar R; Kim DDH
    Transplant Cell Ther; 2023 Feb; 29(2):120.e1-120.e9. PubMed ID: 36460202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment-Sensitive and Treatment-Dependent Chronic Graft-versus-Host Disease Yield Superior Failure-Free and Overall Survival Compared to Treatment-Resistant Chronic Graft-versus-Host Disease.
    El Jurdi N; Herzog S; Shanley R; Holtan SG; MacMillan ML; Weisdorf DJ
    Transplant Cell Ther; 2024 Jun; 30(6):616-625. PubMed ID: 38479549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolated massive pleural effusion as a manifestation of chronic graft versus host disease successfully treated with corticosteroid.
    Masuda Y; Yamazaki S; Honda A; Masamoto Y; Kurokawa M
    Ann Hematol; 2024 Apr; 103(4):1403-1407. PubMed ID: 38285080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spectacular and Prompt Response to Extracorporeal Photopheresis for Refractory Cutaneous Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.
    Spałek A; Grygoruk-Wiśniowska I; Gruenpeter K; Panz-Klapuch M; Helbig G
    Medicina (Kaunas); 2022 Nov; 58(12):. PubMed ID: 36556924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study.
    Liu J; Fan Z; Xu N; Ye J; Chen Y; Shao R; Sun Y; Wu Q; Liu Q; Jin H
    Ann Hematol; 2023 Oct; 102(10):2865-2877. PubMed ID: 37474631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updates in chronic graft-versus-host disease management.
    Malard F; Mohty M
    Am J Hematol; 2023 Oct; 98(10):1637-1644. PubMed ID: 37483142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease.
    Lin C; DiCioccio RA; Haykal T; McManigle WC; Li Z; Anand SM; Poe JC; Bracken SJ; Jia W; Alyea EP; Cardones AR; Choi T; Gasparetto C; Grunwald MR; Hennig T; Kang Y; Long GD; Lopez R; Martin M; Minor KK; Quinones VLP; Sung AD; Wiggins K; Chao NJ; Horwitz ME; Rizzieri DA; Sarantopoulos S
    Transplant Cell Ther; 2023 Mar; 29(3):179.e1-179.e10. PubMed ID: 36577483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of chronic graft-versus-host-disease on intensive care outcome in allogeneic hematopoietic stem cell recipients.
    Lueck C; Tzalavras A; Wohlfarth P; Meedt E; Kiehl M; Turki AT; Hoeper MM; Eder M; Cserna J; Buchtele N; Wolff D; Schellongowski P; Beutel G; Liebregts T
    Bone Marrow Transplant; 2023 Mar; 58(3):303-310. PubMed ID: 36496524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recent advances in prevention and treatment of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation].
    Toubai T; Hosokawa Y
    Rinsho Ketsueki; 2024; 65(5):401-411. PubMed ID: 38825520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.
    Wang D; Liu Y; Lai X; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y
    Front Immunol; 2021; 12():673636. PubMed ID: 34276662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
    Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D
    Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results.
    Apisarnthanarax N; Donato M; Körbling M; Couriel D; Gajewski J; Giralt S; Khouri I; Hosing C; Champlin R; Duvic M; Anderlini P
    Bone Marrow Transplant; 2003 Mar; 31(6):459-65. PubMed ID: 12665841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population-based real-world registry study to evaluate clinical outcomes of chronic graft-versus-host disease.
    Novitzky-Basso I; Schain F; Batyrbekova N; Webb T; Remberger M; Keating A; Mattsson J
    PLoS One; 2023; 18(3):e0282753. PubMed ID: 36893113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Center Volume on Chronic Graft Versus Host Disease in Patients With Allogeneic Stem Cell Transplantation.
    Shimomura Y; Kitamura T; Murata M; Matsuo K; Ito Y; Ichinohe T; Hashii Y; Goto H; Kato K; Ishimaru F; Sato A; Onizuka M; Yanagisawa A; Ohbiki M; Tabuchi K; Atsuta Y; Fukuda T; Kanda J; Terakura S
    Transplant Cell Ther; 2024 Mar; 30(3):326.e1-326.e14. PubMed ID: 38218451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare resource utilization and costs among patients with steroid-resistant chronic graft-versus-host disease in the United States: a retrospective claims database analysis.
    Yu J; Lal LS; Anderson A; DuCharme M; Parasuraman S; Weisdorf D
    Curr Med Res Opin; 2021 May; 37(5):755-759. PubMed ID: 33615925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.